The	0	3	O
beta-1-adrenergic	4	21	O
receptor	22	30	O
,	30	31	O
a	32	33	O
key	34	37	O
cell	38	42	O
surface	43	50	O
signaling	51	60	O
protein	61	68	B-Protein
expressed	69	78	O
in	79	81	O
the	82	85	O
heart	86	91	O
and	92	95	O
other	96	101	O
organs	102	108	O
,	108	109	O
mediates	110	118	O
the	119	122	O
actions	123	130	O
of	131	133	O
catecholamines	134	148	O
in	149	151	O
the	152	155	O
sympathetic	156	167	O
nervous	168	175	O
system	176	182	O
.	182	183	O

Mason	184	189	O
et	190	192	O
al	193	195	O
.	195	196	O

(	197	198	O
1999	198	202	O
)	202	203	O
identified	204	214	O
a	215	216	O
C-to-G	217	223	O
transversion	224	236	B-Variation
in	237	239	O
the	240	243	O
intracellular	244	257	O
cytoplasmic	258	269	O
tail	270	274	O
near	275	279	O
the	280	283	O
seventh	284	291	O
transmembrane-spanning	292	314	O
segment	315	322	O
of	323	325	O
the	326	329	O
human	330	335	O
ADRB1	336	341	B-Gene
gene	342	346	O
,	346	347	O
resulting	348	357	B-Regulation
in	358	360	I-Regulation
an	361	363	O
arg389-to-gly	364	377	O
substitution	378	390	B-Variation
(	391	392	O
R389G	392	397	O
)	397	398	O
.	398	399	O

Allele	400	406	O
frequencies	407	418	O
for	419	422	O
gly389	423	429	O
and	430	433	O
arg389	434	440	O
residues	441	449	O
were	450	454	O
0.26	455	459	O
and	460	463	O
0.74	464	468	O
,	468	469	O
respectively	470	482	O
(	483	484	O
the	484	487	O
former	488	494	O
had	495	498	O
previously	499	509	O
been	510	514	O
considered	515	525	O
as	526	528	O
the	529	532	O
human	533	538	O
wildtype	539	547	O
ADRB1	548	553	B-Gene
allele	554	560	O
)	560	561	O
.	561	562	O

Using	563	568	O
site-directed	569	582	O
mutagenesis	583	594	O
to	595	597	O
mimic	598	603	O
the	604	607	O
2	608	609	O
variants	610	618	B-Variation
,	618	619	O
cultured	620	628	O
cells	629	634	O
were	635	639	O
permanently	640	651	O
transfected	652	663	O
to	664	666	O
express	667	674	O
the	675	678	O
gly389	679	685	O
and	686	689	O
arg389	690	696	O
receptors	697	706	O
.	706	707	O

In	708	710	O
functional	711	721	O
studies	722	729	O
with	730	734	O
matched	735	742	O
expression	743	753	B-Molecular_Physiological_Activity
,	753	754	O
the	755	758	O
arg389	759	765	O
receptors	766	775	O
had	776	779	O
slightly	780	788	O
higher	789	795	B-Positive_Regulation
basal	796	801	O
levels	802	808	O
of	809	811	O
adenylyl	812	820	B-Enzyme
cyclase	821	828	I-Enzyme
activities	829	839	B-Molecular_Physiological_Activity
.	839	840	O

However	841	848	O
,	848	849	O
maximal	850	857	O
isoproterenol-stimulated	858	882	O
levels	883	889	O
were	890	894	O
markedly	895	903	O
higher	904	910	B-Positive_Regulation
for	911	914	O
the	915	918	O
arg389	919	925	O
receptor	926	934	O
as	935	937	O
compared	938	946	O
with	947	951	O
the	952	955	O
gly389	956	962	O
receptor	963	971	O
.	971	972	O

Agonist-promoted	973	989	O
binding	990	997	B-Interaction
was	998	1001	O
also	1002	1006	O
increased	1007	1016	B-Positive_Regulation
for	1017	1020	O
the	1021	1024	O
arg389	1025	1031	O
receptor	1032	1040	O
,	1040	1041	O
consistent	1042	1052	O
with	1053	1057	O
enhanced	1058	1066	B-Positive_Regulation
coupling	1067	1075	B-Interaction
to	1076	1078	O
stimulatory	1079	1090	O
G	1091	1092	O
protein	1093	1100	B-Protein
(	1101	1102	O
Gs	1102	1104	O
;	1104	1105	O
see	1106	1109	O
139320	1110	1116	O
)	1116	1117	O
and	1118	1121	O
increased	1122	1131	B-Positive_Regulation
adenylyl	1132	1140	B-Enzyme
cyclase	1141	1148	I-Enzyme
activation	1149	1159	B-Molecular_Physiological_Activity
.	1159	1160	O

These	1161	1166	O
and	1167	1170	O
other	1171	1176	O
studies	1177	1184	O
indicated	1185	1194	O
that	1195	1199	O
this	1200	1204	O
polymorphic	1205	1216	O
variation	1217	1226	B-Variation
of	1227	1229	O
the	1230	1233	O
human	1234	1239	O
ADRB1	1240	1245	B-Gene
gene	1246	1250	O
results	1251	1258	O
in	1259	1261	O
alterations	1262	1273	B-Regulation
of	1274	1276	O
receptor-Gs	1277	1288	O
interaction	1289	1300	B-Interaction
with	1301	1305	O
functional	1306	1316	O
consequences	1317	1329	O
on	1330	1332	O
signal	1333	1339	O
transduction	1340	1352	O
,	1352	1353	O
consistent	1354	1364	O
with	1365	1369	O
its	1370	1373	O
localization	1374	1386	O
in	1387	1389	O
a	1390	1391	O
putative	1392	1400	O
G-protein	1401	1410	O
binding	1411	1418	B-Interaction
domain	1419	1425	O
.	1425	1426	O

Mason	1427	1432	O
et	1433	1435	O
al	1436	1438	O
.	1438	1439	O

(	1440	1441	O
1999	1441	1445	O
)	1445	1446	O
suggested	1447	1456	O
that	1457	1461	O
the	1462	1465	O
genetic	1466	1473	O
variation	1474	1483	B-Variation
of	1484	1486	O
the	1487	1490	O
ADRB1	1491	1496	B-Gene
gene	1497	1501	O
may	1502	1505	O
be	1506	1508	O
the	1509	1512	O
basis	1513	1518	O
of	1519	1521	O
interindividual	1522	1537	O
differences	1538	1549	O
in	1550	1552	O
pathophysiologic	1553	1569	O
characteristics	1570	1585	O
or	1586	1588	O
in	1589	1591	O
the	1592	1595	O
response	1596	1604	O
to	1605	1607	O
therapeutic	1608	1619	O
beta-adrenergic	1620	1635	O
receptor	1636	1644	O
agonists	1645	1653	O
and	1654	1657	O
antagonists	1658	1669	O
in	1670	1672	O
cardiovascular	1673	1687	O
and	1688	1691	O
other	1692	1697	O
diseases	1698	1706	O
.	1706	1707	O

